about
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cellsThe histone deacetylase SIRT2 stabilizes Myc oncoproteinsLarge-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serumThe prenatal origins of cancerAmide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.Histone deacetylase inhibitors: multifunctional anticancer agents.The retinoid anticancer signal: mechanisms of target gene regulation.Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.INPP4B is an oncogenic regulator in human colon cancer.Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradationIGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.Upregulation of LYAR induces neuroblastoma cell proliferation and survival.TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach.PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injuryHyperalgesia due to nerve injury—role of peroxynitriteATP P2X receptors play little role in the maintenance of neuropathic hyperalgesiaConcentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control studyZinc alleviates thermal hyperalgesia due to partial nerve injuryFree radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injuryCombination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastomaThe histone chaperone complex FACT promotes proliferative switch of G0 cancer cellsJMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesisThe long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35LncRNA REG1CP promotes tumorigenesis through an enhancer complex to recruit FANCJ helicase for REG3A transcriptionJMJD6 is a tumorigenic factor and therapeutic target in neuroblastomaRecognition of CRISPR/Cas9 off-target sites through ensemble learning of uneven mismatch distributions
P50
Q24297046-5EE81C7F-3CC3-4306-A1EC-60FD728ECD5EQ24622277-CE87D707-5430-4B22-8ABE-B6F9DD7833DAQ30452357-78000743-CAB7-4AF9-BA25-C0522D238F97Q33697463-4E1A3731-5368-405C-B7D7-E68B88F75EC9Q34397568-672B48D5-2ECA-489E-8871-43C8B8D11F9EQ36169695-FEA183E9-37A3-43F4-A754-AA3420F3FA08Q36413439-B254107C-5785-449D-8B06-D0210138CA71Q36615158-ABBB1A95-8C30-48CF-9DA0-F5E1C1B35ACAQ36985083-0B55E9D8-F4BD-498A-B155-76CF490DB5F0Q37005755-5E71D442-E055-4FCA-9FFA-D99BC001EC65Q37482721-5CF22D36-860A-44C7-8E73-79026E16505CQ38300565-EE4018FD-9F28-4DF2-A91B-C1DF1330CAFDQ38689375-11E9793A-B01A-49AC-A0BA-45EAA5EA3130Q38946342-A0039389-4414-4BA1-8C47-07D0E19E25BDQ39028675-5466E732-8D33-463A-89CD-A7DE0D7E25BCQ39228542-9D7AE49B-51F9-408A-8534-3FEF09C8AF66Q39294214-3A4EEC05-43FD-416D-ABD3-ADD44BF2107EQ40436424-11D6F201-2578-4243-A601-512A87AF370EQ53083996-600079C3-ADDF-45D1-AEFA-2CE9721B96B4Q53456124-D01FB7CD-6E29-46D1-95F7-00671623E562Q60687157-3149B48E-16C1-4308-B6BD-C4090974E5A8Q60687159-E2FADC99-94A8-455E-A2BE-9D8658E430C5Q73892181-74BFB7AB-343F-4EFD-97AB-39A9AB34E091Q74387491-AA102C97-3129-4D84-89DD-A8507085BC5FQ77919144-CF84072E-1E41-443A-A0E7-ED3CD9AEAAFDQ77937081-5EDCC42E-E0BE-4AA2-ACE8-7EF60DF53D5BQ89840105-CE836D9D-699C-471B-9983-2EA8157A0095Q90481352-216B7C7A-71FA-4F77-8121-F510976F324AQ90949896-50AA6366-AC11-42C2-8E70-F5997164382FQ91129944-877CDD8F-2B8F-4310-9417-AD10FD349F07Q91451646-71CFC12E-F23D-45C8-87FC-51681361ABD6Q92185923-2ECA13B4-82EB-4F10-B57C-E463092D3D4FQ93035440-A7D257AA-715E-4625-AA1C-4F724BE1BF4F
P50
description
researcher ORCID 0000-0001-6244-7316
@en
name
Tao Liu
@ast
Tao Liu
@en
Tao Liu
@es
Tao Liu
@nl
type
label
Tao Liu
@ast
Tao Liu
@en
Tao Liu
@es
Tao Liu
@nl
prefLabel
Tao Liu
@ast
Tao Liu
@en
Tao Liu
@es
Tao Liu
@nl
P106
P1153
56461551200
P2456
P31
P496
0000-0001-6244-7316